MitraClip European approval
This article was originally published in The Gray Sheet
Executive SummaryEvalve's MitraClip percutaneous mitral valve repair system gains CE mark approval, the firm announces March 25. Evalve says it is the first commercially available device for nonsurgical treatment of mitral regurgitation. The randomized arm of a multi-center pivotal trial for U.S. approval (EVEREST) is expected to complete enrollment by the end of the year
You may also be interested in...
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.